Last reviewed · How we verify
Bevacizumab or Bevacizumab biosimilar
Bevacizumab or Bevacizumab biosimilar is a Small molecule drug developed by BeiGene. It is currently in Phase 1 development.
At a glance
| Generic name | Bevacizumab or Bevacizumab biosimilar |
|---|---|
| Sponsor | BeiGene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab or Bevacizumab biosimilar CI brief — competitive landscape report
- Bevacizumab or Bevacizumab biosimilar updates RSS · CI watch RSS
- BeiGene portfolio CI
Frequently asked questions about Bevacizumab or Bevacizumab biosimilar
What is Bevacizumab or Bevacizumab biosimilar?
Bevacizumab or Bevacizumab biosimilar is a Small molecule drug developed by BeiGene.
Who makes Bevacizumab or Bevacizumab biosimilar?
Bevacizumab or Bevacizumab biosimilar is developed by BeiGene (see full BeiGene pipeline at /company/beigene).
What development phase is Bevacizumab or Bevacizumab biosimilar in?
Bevacizumab or Bevacizumab biosimilar is in Phase 1.